Recent Updates — CLOV

Clover Health Investments, Corp. appointed former U.S. Senator Robert G. Torricelli as a Class I director and Dr. Brian J. Miller as a Class III director to fill previously disclosed vacancies on its Board of Directors. The appointments bring the total board size to nine directors. Senator Torricelli will serve on the Audit Committee, while Dr. Miller will join the Clinical Committee. Each new director receives a pro rata portion of the annual retainer and an RSU award valued at $200,000, prorated for service through December 31, 2026. Clover Health is a physician enablement technology company providing Medicare Advantage plans and clinical decision-support software.

On September 22, 2026, Clover Health Investments appointed former U.S. Senator Robert G. Torricelli as a Class I director and Dr. Brian J. Miller as a Class III director to fill previously disclosed vacancies, bringing the Board size to nine members. Torricelli joins the Audit Committee while Miller serves on the Clinical Committee. Each appointee receives a pro-rated annual retainer and an RSU award valued at $200,000 for 2026 service. The company operates in the healthcare technology sector, providing physician enablement software and Medicare Advantage insurance plans.

Clover Health Investments, Corp. reported a cybersecurity incident on July 4, 2026, where a threat actor gained access to three non-managerial health plan employee accounts via social engineering. The compromised accounts had access to personally identifiable information and protected health information but no access to corporate financial or claims systems. The company believes the incident has no material impact on its business, financial condition, or results of operations. Clover Health is a healthcare technology and insurance company.